Tearsheet
Investment Highlights Market Valuation Price Chart Business Description Interactive Breakdown Latest Trefis Analyses Better Bets vs. REGN Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

Regeneron Pharmaceuticals (REGN)

Market Price (9/17/2025): $574.39 | Market Cap: $60.4 Bil
Sector: Health Care | Industry: Biotechnology

Regeneron Pharmaceuticals (REGN)

Market Price (9/17/2025): $574.39
Market Cap: $60.4 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights

0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.2%, FCF Yield is 5.9%		 Weak multi-year price returns
2Y Excs Rtn is -79%, 3Y Excs Rtn is -83%		 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27%		  
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 25%, CFO LTM is 4.7 Bil, FCF LTM is 3.6 Bil		  
3 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%		  
4 Low stock price volatility
Vol 12M is 39%		  
0 Attractive yield
Total YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.7%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.2%, FCF Yield is 5.9%
1 Attractive operating margins
Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 27%
2 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 33%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 25%, CFO LTM is 4.7 Bil, FCF LTM is 3.6 Bil
3 Valuation becoming less expensive
P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -28%
4 Low stock price volatility
Vol 12M is 39%
5 Weak multi-year price returns
2Y Excs Rtn is -79%, 3Y Excs Rtn is -83%
6 Weak revenue growth
Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.3%

Market Valuation

 9/17/252024202320222021
Share Price CYE$574.39$709.29$874.54$718.41$628.82
Market Cap CYE ($ Bil)60.476.393.176.766.8
Total Debt ($ Bil)2.72.72.72.72.7
Total Cash ($ Bil)7.59.010.87.75.7
Enterprise Value ($ Bil)55.679.095.879.469.5
Valuation Ratios     
P/S TTM4.25.47.16.34.2
P/EBIT TTM12.315.921.915.77.1
P/E TTM13.517.423.717.88.3
Sector Ratios     
P/S TTM (Sector)3.73.64.14.57.3
P/EBIT TTM (Sector)-1.6-1.3-1.4-1.3-2.9
P/E TTM (Sector)-1.8-1.5-1.5-1.3-2.9
 9/17/2520242023
Share Price CYE$574.39$709.29$874.54
Market Cap CYE ($ Bil)60.476.393.1
Total Debt ($ Bil)2.72.72.7
Total Cash ($ Bil)7.59.010.8
Enterprise Value ($ Bil)55.679.095.8
Valuation Ratios   
P/S TTM4.25.47.1
P/EBIT TTM12.315.921.9
P/E TTM13.517.423.7
Sector Ratios   
P/S TTM (Sector)3.73.64.1
P/EBIT TTM (Sector)-1.6-1.3-1.4
P/E TTM (Sector)-1.8-1.5-1.5

Market Cap Chart

Business Description

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Show more

Price Returns Compared

Expand for Detailed View

 202020212022202320242025Total [1]
Returns
REGN Return29%31%14%22%-19%-19%50%
Peers Return1%13%20%-0%-8%6%32%
S&P 500 Return16%27%-19%24%23%12%104%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: AMGN, GILD, BIIB, BMRN, ABBV. See REGN Returns vs. Peers.
[3] 2025 data is for the year up to 9/16/2025 (YTD)

Better Bets than Regeneron Pharmaceuticals (REGN)

 REGNBetter Performance than REGN
MetricValueIndustry (Biotechnology)
Rev Chg LTM5.4%ABBV (6.1%), AMGN (12.9%), VRTX (10.5%), ALNY (17.2%), INSM (21.2%)
Rev Chg 3Y Avg0.3%ABBV (0.6%), AMGN (10.0%), GILD (1.6%), VRTX (11.0%), ALNY (40.8%)
Op Mgn LTM27.0%GILD (37.4%), UTHR (50.1%), RPRX (79.8%), EXEL (33.7%), HALO (57.9%)
CFO/Rev LTM33.4%AMGN (34.4%), GILD (34.2%), VRTX (33.7%), UTHR (44.6%), RPRX (104.4%)
FCF/Rev LTM25.0%ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), UTHR (34.8%)
Total Yield7.7%AMGN (7.9%), RPRX (9.3%), PTCT (13.5%), CPRX (8.5%), AGIO (30.6%)
 REGNBetter Performance than REGN
MetricValueAll Other Sectors
Rev Chg LTM5.4%NVDA (71.6%), MSFT (14.9%), AAPL (6.0%), GOOGL (13.1%), AMZN (10.9%)
Rev Chg 3Y Avg0.3%NVDA (92.0%), MSFT (12.5%), AAPL (1.8%), GOOGL (10.2%), AMZN (11.3%)
Op Mgn LTM27.0%NVDA (58.1%), MSFT (45.6%), AAPL (31.9%), GOOGL (32.7%), META (42.9%)
CFO/Rev LTM33.4%NVDA (46.6%), MSFT (48.3%), GOOGL (36.0%), META (56.4%), AVGO (42.4%)
FCF/Rev LTM25.0%NVDA (43.6%), MSFT (25.4%), META (30.7%), AVGO (41.6%), V (56.8%)
Total Yield7.7%XOM (9.7%), BABA (38.9%), CVX (9.3%), WFC (9.8%), TM (2104.3%)

Latest Trefis Analyses

TitleTopicDate
0DASHBOARDS  
1Regeneron Pharmaceuticals Earnings Notes  
2Regeneron Pharmaceuticals vs Gilead Sciences: Which Is A Better Investment?Counter-Intuitive Comparisons 
3How Does REGN Stack Up Against Its Peers?Peer Comparison 
4Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, SO   
5Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, UTHR   
6Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UTHR, EXEL   
7Day 5 of Gains Streak for Regeneron Pharmaceuticals Stock with 6% Return (vs. -20% YTD) [7/14/2025]  
8REGN Dip Buy Analysis  
9REGN YTD Stock Return Of -22% Outperforms BIIB by 1.9% and Underperforms GILD by -37%Return 
10Regeneron Pharmaceuticals vs. Out Of Favor Health Care Stocks: Which Is A Better Investment?Investment Theme Comparisons 
11ARTICLES  
12REGN Stock Up 6% after 5-Day Win Streak July 15th, 2025
13Is It Time To Buy Regeneron Pharmaceuticals Stock? June 2nd, 2025
14Is Regeneron Stock Fully Valued At $820? September 8th, 2023
15Is A Fall Imminent For Regeneron Stock After A Stellar 25% Rise In A Week? September 12th, 2022
16Will Regeneron Stock Rebound After Its Recent 6% Fall? January 7th, 2022
Title
0DASHBOARDS
1REGN Stock Up 6% after 5-Day Win Streak
2Is It Time To Buy Regeneron Pharmaceuticals Stock?
3Is Regeneron Stock Fully Valued At $820?
4Is A Fall Imminent For Regeneron Stock After A Stellar 25% Rise In A Week?
5Will Regeneron Stock Rebound After Its Recent 6% Fall?
6ARTICLES
7Regeneron Pharmaceuticals Earnings Notes
8Regeneron Pharmaceuticals vs Gilead Sciences: Which Is A Better Investment?
9How Does REGN Stack Up Against Its Peers?
10Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, SO 
11Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UNH, UTHR 
12Better Bet Than REGN Stock: Pay Less Than Regeneron Pharmaceuticals To Get More From UTHR, EXEL 
13Day 5 of Gains Streak for Regeneron Pharmaceuticals Stock with 6% Return (vs. -20% YTD) [7/14/2025]
14REGN Dip Buy Analysis
15REGN YTD Stock Return Of -22% Outperforms BIIB by 1.9% and Underperforms GILD by -37%
16Regeneron Pharmaceuticals vs. Out Of Favor Health Care Stocks: Which Is A Better Investment?

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical11963.5%11963.5%
2GIBOGIBO9734.4% 
3CHSNChanson International7565.0%-99.3%
4LNZALanzaTech Global7287.5%-86.0%
5QMMMQMMM3031.7%6775.0%
6OESXOrion Energy Systems1497.9%22.9%
7CURXCuranex Pharmaceuticals1401.6%1401.6%
8ENTOEntero Therapeutics565.6%117.6%
9PTNMPitanium553.2% 
10WLDSWearable Devices449.5%-30.0%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1CJETChijet Motor-92.2%-95.0%
2STFSStar Fashion Culture-92.2%-97.8%
3ELPWElong Power-91.6%-76.7%
4NXTTNext Technology-89.6%-95.1%
5NAKAKindly MD-89.0% 
6BINIBollinger Innovations-88.9%-100.0%
7JEM707 Cayman-88.4%-98.2%
8YAASYouxin Technology-82.5%-98.3%
9NEONNeonode-82.0%-50.2%
10NVNOenVVeno Medical-81.5%-69.8%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1BDSXBiodesix1313.2%-78.6%
2CLSDClearside Biomedical954.0%-74.9%
3SDOTSadot624.1%-79.4%
4WLDSWearable Devices498.0%-30.0%
5CHEKCheck-Cap285.6%154.6%
6ATCHAtlasClear275.9%-91.0%
7HSDTHelius Medical Technologies262.5%-95.6%
8OPIOffice Properties Income Trust261.7%-13.4%
9FGIFGI Industries156.8%145.2%
10AIREReAlpha Tech154.0%-56.1%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1NAKAKindly MD-81.4% 
2ATYRaTyr Pharma-79.7%-70.2%
3LGCLLucas GC-73.6%-77.1%
4EPSMEpsium Enterprise-70.1% 
5BNGOBionano Genomics-59.4%-89.7%
6FAASDigiAsia-58.5%-87.2%
7QMMMQMMM-57.5%6775.0%
8VCIGVCI Global-56.9%-99.1%
9YYGHYY-56.6%-78.5%
10XAGELongevity Health-55.5%-86.1%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Regeneron Pharmaceuticals

Financials

REGNAMGNGILDBIIBBMRNABBVMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.AbbVie  
Mkt Price575.06273.08110.86143.6853.94216.26179.97
Mkt Cap60.4146.9138.021.010.4382.399.2
Rev LTM14,21434,91728,8629,8163,06458,32821,538
Op Inc LTM3,8418,19210,7972,27477613,6956,016
FCF LTM3,55610,6059,3692,29669118,2396,463
FCF 3Y Avg3,2488,5908,3971,66731520,2735,823
CFO LTM4,74412,0139,8682,58276719,2837,306
CFO 3Y Avg4,5189,7538,9491,96841921,1546,733

Growth & Margins

REGNAMGNGILDBIIBBMRNABBVMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.AbbVie  
Rev Chg LTM5.4%12.9%3.8%1.6%18.4%6.1%5.7%
Rev Chg 3Y Avg0.3%10.0%1.6%-3.1%17.0%0.6%1.1%
Rev Chg Q3.6%9.4%1.8%6.1%15.9%6.6%6.4%
QoQ Delta Rev Chg LTM0.9%2.3%0.4%1.5%3.8%1.7%1.6%
Op Mgn LTM27.0%23.5%37.4%23.2%25.3%23.5%24.4%
Op Mgn 3Y Avg30.1%26.4%39.2%23.4%14.0%27.2%26.8%
QoQ Delta Op Mgn LTM-0.2%1.6%-0.0%0.2%4.3%1.0%0.6%
CFO/Rev LTM33.4%34.4%34.2%26.3%25.0%33.1%33.2%
CFO/Rev 3Y Avg33.6%32.0%31.9%20.0%15.0%37.5%31.9%
FCF/Rev LTM25.0%30.4%32.5%23.4%22.6%31.3%27.7%
FCF/Rev 3Y Avg24.1%28.2%30.0%16.9%10.9%36.0%26.1%

Valuation

REGNAMGNGILDBIIBBMRNABBVMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.AbbVie  
Mkt Cap60.4146.9138.021.010.4382.399.2
P/S4.34.24.82.13.46.64.2
P/EBIT12.314.216.810.512.264.913.2
P/E13.622.221.914.215.7101.618.8
P/CFO12.712.214.08.113.519.813.1
Total Yield7.7%7.9%7.4%7.0%6.3%3.9%7.2%
Dividend Yield0.3%3.4%2.9%0.0%0.0%3.0%1.6%
FCF Yield 3Y Avg4.4%6.2%8.0%6.6%2.7%7.3%6.4%
D/E0.00.40.20.30.10.20.2
Net D/E-0.10.30.10.2-0.10.20.2

Returns

REGNAMGNGILDBIIBBMRNABBVMedian
NameRegenero.Amgen Gilead S.Biogen BioMarin.AbbVie  
1M Rtn-0.8%-7.9%-5.7%3.7%-6.3%4.6%-3.2%
3M Rtn13.2%-5.1%3.4%13.5%-1.9%17.6%8.3%
6M Rtn-13.3%-12.8%2.0%0.4%-24.6%2.9%-6.2%
12M Rtn-49.9%-15.8%37.3%-28.0%-22.8%14.4%-19.3%
3Y Rtn-18.7%30.0%88.1%-31.0%-38.9%68.0%5.7%
1M Excs Rtn-3.2%-10.3%-8.1%1.2%-8.7%2.2%-5.7%
3M Excs Rtn0.7%-16.4%-8.8%0.1%-13.6%4.8%-4.3%
6M Excs Rtn-31.4%-28.9%-16.3%-16.3%-41.0%-13.8%-22.6%
12M Excs Rtn-68.5%-32.6%20.5%-45.5%-54.1%-2.6%-39.0%
3Y Excs Rtn-82.7%-41.1%28.7%-94.6%-104.4%8.7%-61.9%

Comparison Analyses

Title
0How Does REGN Stack Up Against Its Peers?
1Regeneron Pharmaceuticals vs. Jazz Pharmaceuticals: With Return Forecast Of 133%, Jazz Pharmaceuticals Is A Better Bet
2BMRN Looks Stronger Than REGN With 46% Return Potential
3Regeneron Pharmaceuticals vs. Zoetis: With Return Forecast Of 59%, Regeneron Pharmaceuticals Is A Better Bet
4Regeneron Pharmaceuticals vs. Mondelez: With Return Forecast Of 59%, Regeneron Pharmaceuticals Is A Better Bet
5Regeneron Pharmaceuticals vs. 3M Company: With Return Forecast Of 59%, Regeneron Pharmaceuticals Is A Better Bet
6Regeneron Pharmaceuticals vs. Abbott Laboratories: With Return Forecast Of 35%, Regeneron Pharmaceuticals Is A Better Bet
7Regeneron Pharmaceuticals vs. Thermo Fisher Scientific: With Return Forecast Of 35%, Regeneron Pharmaceuticals Is A Better Bet
8Regeneron Pharmaceuticals vs. Home Depot: With Return Forecast Of 35%, Regeneron Pharmaceuticals Is A Better Bet
9Regeneron Pharmaceuticals vs. Automatic Data Processing: Similar Revenue, But Regeneron Pharmaceuticals Is A Better Bet

Financials

$ Mil | FY: 12/312025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q42022Q3
Period End6/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/20229/30/2022
Filing Date8/1/20254/29/20252/5/202510/31/20248/1/20245/2/20242/5/202411/2/20238/3/20235/4/20232/6/202311/3/2022
Key Financials Quarterly            
Total Revenue3,6763,0293,7893,7213,5473,1453,4343,3633,1583,1623,4142,936
Ebitda1,6571,0411,0951,6281,7648311,2791,2341,2059761,4421,618
Operating Income1,0805929901,1801,0707519731,1111,0169471,1471,224
Net Income1,3928099181,3411,4327221,1601,0089688181,1971,316
EPS13.247.588.5312.4013.256.7010.889.489.057.6411.1912.31
Key Financials TTM            
Total Revenue TTM14,21414,08614,20213,84713,48913,10013,11713,09712,67112,37012,17313,710
Ebitda TTM5,4225,5285,3185,5025,1074,5494,6934,8575,2405,0865,2606,409
Operating Income TTM3,8413,8313,9913,9733,9053,8524,0474,2214,3344,4274,7396,232
Net Income TTM4,4594,4994,4134,6544,3223,8583,9543,9914,2994,1834,3385,370
Growth Rates Quarterly            
Total Revenue Growth3.6%-3.7%10.3%10.6%12.3%-0.5%0.6%14.5%10.5%6.6%-31.0%-15.0%
EBITDA Growth-6.0%25.2%-14.4%32.0%46.4%-14.8%-11.3%-23.7%14.7%-15.1%-44.4%-15.0%
Operating Income Growth0.9%-21.3%1.8%6.2%5.2%-20.6%-15.2%-9.2%-8.4%-24.8%-56.6%-33.8%
Net Income Growth-2.8%12.0%-20.9%33.0%47.9%-11.7%-3.1%-23.4%13.6%-16.0%-46.3%-19.4%
Margins Quarterly            
EBITDA Margin45.1%34.4%28.9%43.8%49.7%26.4%37.2%36.7%38.2%30.8%42.2%55.1%
Operating Income Margin29.4%19.5%26.1%31.7%30.2%23.9%28.3%33.0%32.2%29.9%33.6%41.7%
Net Income Margin37.9%26.7%24.2%36.0%40.4%23.0%33.8%30.0%30.7%25.9%35.1%44.8%
Cash & Debt            
Total Cash7,4708,3499,0129,7969,80910,52010,8459,9148,9288,9607,7427,022
Total Debt2,7052,7052,7042,7042,7042,7032,7032,7032,7022,7022,7012,701
Net Debt / (Cash)-4,764-5,645-6,308-7,092-7,105-7,816-8,142-7,211-6,226-6,258-5,041-4,321
Cash Flows Quarterly            
FCF from Operations1,1441,0451,2631,2913541,5121,0901,1141,0221,3681,720629
Cash Flows TTM            
FCF from Operations TTM4,7443,9534,4204,2474,0704,7394,5945,2244,7394,2815,0155,668
Returns to Shareholders Quarterly            
Dividends93940000000000
Share Repurchases1,0671,0461,2268559166357476767058086201,044
Return on Invested Capital (ROIC) Quarterly            
ROIC------------
Return on Invested Capital (ROIC) TTM            
ROIC TTM------------

Segment Financials

Revenue by Segment

$ Mil20242023202220212020
EYLEA ®5,7206,2655,7924,9474,644
Collaboration revenue5,5034,9143,673  
Libtayo ®539374306271176
Other revenue536365281557174
Libtayo324730  
Praluent ®182130170151 
EYLEA HD ®16600  
Evkeeza ®774918  
Inmazeb ®7030  
ARCALYST ®  21314
REGEN-COV ®  5,828186 
Bayer   1,1861,146
Sanofi   1,186404
Total13,11712,17316,0728,4976,558


Price Behavior

REGN Betas & Captures as of 8/31/2025

 1M2M3M6M1Y3Y
Beta-0.170.270.400.630.670.61
Up Beta0.040.250.030.520.570.53
Down Beta-1.35-1.18-0.500.360.530.55
Up Capture50%100%111%71%29%28%
Bmk +ve Days10223571142415
Stock +ve Days12223463115388
Down Capture-59%40%39%117%117%93%
Bmk -ve Days11192754106334
Stock -ve Days9202862133362

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date8292025
Short Interest: Shares Quantity2,827,689
Short Interest: % Change Since 815202520.4%
Average Daily Volume959,124
Days-to-Cover Short Interest2.95
Basic Shares Quantity105,100,000
Short % of Basic Shares2.7%

Returns Analyses

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
8/1/20252.5%2.6%6.6%
4/29/2025-6.9%-1.2%-3.0%
1/13/20252.9%-2.2%-4.5%
10/31/2024-9.2%-11.5%-18.7%
8/1/20241.3%-1.1%9.2%
5/2/20243.8%5.8%8.5%
2/2/2024-1.3%-1.2%1.4%
11/2/20233.5%4.0%3.0%
...
SUMMARY STATS   
# Positive181114
# Negative71411
Median Positive3.4%5.8%7.6%
Median Negative-3.7%-1.9%-4.5%
Max Positive6.9%10.7%32.9%
Max Negative-9.2%-11.5%-18.7%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025801202510-Q 6/30/2025
3312025429202510-Q 3/31/2025
12312024205202510-K 12/31/2024
93020241031202410-Q 9/30/2024
6302024801202410-Q 6/30/2024
3312024502202410-Q 3/31/2024
12312023205202410-K 12/31/2023
93020231102202310-Q 9/30/2023
6302023803202310-Q 6/30/2023
3312023504202310-Q 3/31/2023
12312022206202310-K 12/31/2022
93020221103202210-Q 9/30/2022
6302022803202210-Q 6/30/2022
3312022504202210-Q 3/31/2022
12312021207202210-K 12/31/2021
93020211104202110-Q 9/30/2021

Insider Activity

Expand for More

 OwnerTitleFiling DateActionPriceSharesTransacted
Value		Value of
Held Shares		Form
0RYAN ARTHUR F 10032024Sell1041.3533,12418,410,027Form
1RYAN ARTHUR F 9052024Sell1166.5244,66620,738,393Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.